Ganmaidazao Concentrated Beverage Sleep-Assisting Trial

A human trial with blind method and self-control design was carried out to evaluate the sleep-improving function of a food. Indicators were detected by professional instruments and self-assessed by subjects. Relevant data before and after 28 consecutive days of test sample administration were collected for comparative analysis.

Inclusion Criteria: * Aged 18 to 60 years of any gender, with a history of staying up late or mild sleep disorder, and Pittsburgh Sleep Quality Index (PSQI) score between 7 and 15 points (mild to moderate sleep impairment). * Regular daily schedule with bedtime from 22:00 to 24:30 and wake-up time from 6:30 to 8:30; long-term daily schedule fluctuation ≤ 2 hours, and able to maintain a fixed schedule throughout the trial. * No abnormal saliva secretion and capable of completing saliva sample collection independently and normally. * Body Mass Index (BMI) ranging from 18.5 to 28.0, without extreme emaciation or obesity. * Able to participate in pre-trial centralized training and operational assessments (including wearable bracelet wearing, saliva collection, and questionnaire filling), and pass the assessment before enrollment. * No intake of sleep aids, anti-anxiety drugs, antidepressants, central nervous system regulators, sleep-improving health foods and related products within 2 weeks prior to enrollment. * Free from severe organic diseases, including cardiovascular and cerebrovascular diseases, liver and kidney dysfunction, psychiatric disorders, and nervous system diseases. * Free from severe sleep disorder subtypes, such as obstructive sleep apnea syndrome. * No history of allergy to the ingredients and excipients of the test product, and voluntarily sign the informed consent form. Exclusion Criteria: * Aged under 18 years or over 60 years. * Current smokers, or subjects with alcohol drinking habits of ≥3 times per week who have not quit alcohol within one month before the trial. * Long-term intake of stimulating beverages, defined as drinking strong tea, coffee or energy drinks ≥3 cups per day. * Experienced drastic changes in diet or daily routine within one month before enrollment, such as frequent business trips, travel, shift work, or dramatic dietary habit changes. * Diagnosed with severe sleep disorders or obstructive sleep apnea syndrome. * Participated in other human clinical trials, received professional sleep intervention therapy, or consumed products containing N-acetylneuraminic acid within one month before enrollment. * Pregnant or lactating females, or those planning to become pregnant within one year. * Long-term shift workers, regular severe night owls, or subjects with extremely unstable sleeping environments. * Intolerant to wearing smart wearable bracelets or unable to cooperate with trial-related examinations and sample collection. * Staff of the trial institution and other personnel involved in this project. * Scheduled to receive surgical treatment during the trial period. * With a history of severe food or drug allergies. * Diagnosed with digestive system organic lesions such as gastrointestinal ulcers and bleeding. * Suffering from severe physical and mental illnesses under treatment, severe cardiovascular, cerebrovascular and hematological diseases, severe liver and kidney dysfunction, pulmonary infection or malignant tumors.